home / stock / sndx / sndx quote
Last: | $23.81 |
---|---|
Change Percent: | 3.21% |
Open: | $23.18 |
Close: | $23.07 |
High: | $24.19 |
Low: | $22.71 |
Volume: | 513,887 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$23.81 | $23.18 | $23.07 | $24.19 | $22.71 | 513,887 | 03-28-2024 |
$23.07 | $21.79 | $23.07 | $23.255 | $21.69 | 1,190,922 | 03-27-2024 |
$21.44 | $22.67 | $21.44 | $22.96 | $21.42 | 1,248,893 | 03-26-2024 |
$22.44 | $22.58 | $22.44 | $22.79 | $22.4 | 825,478 | 03-25-2024 |
$22.58 | $22.81 | $22.58 | $22.98 | $22.49 | 1,076,996 | 03-22-2024 |
$22.88 | $23.39 | $22.88 | $23.63 | $22.83 | 1,449,923 | 03-21-2024 |
$23.03 | $22.32 | $23.03 | $23.17 | $22.17 | 1,085,504 | 03-20-2024 |
$22.22 | $21.78 | $22.22 | $22.46 | $21.72 | 996,108 | 03-19-2024 |
$21.92 | $23.37 | $21.92 | $23.55 | $21.88 | 1,873,091 | 03-18-2024 |
$23.52 | $22.58 | $23.52 | $23.73 | $22.43 | 3,569,947 | 03-15-2024 |
$22.65 | $23.53 | $22.65 | $23.8 | $22.34 | 1,107,750 | 03-14-2024 |
$23.76 | $23.68 | $23.76 | $24.21 | $23.08 | 1,075,839 | 03-13-2024 |
$23.86 | $23.77 | $23.86 | $24.08 | $23.05 | 1,483,720 | 03-12-2024 |
$23.57 | $24.51 | $23.57 | $24.85 | $23.29 | 1,074,588 | 03-11-2024 |
$24.57 | $23.76 | $24.57 | $25.16 | $23.67 | 1,674,242 | 03-08-2024 |
$23.47 | $23.82 | $23.47 | $24.51 | $23.42 | 891,994 | 03-07-2024 |
$23.75 | $23.35 | $23.75 | $23.99 | $23.155 | 882,198 | 03-06-2024 |
$22.94 | $23.19 | $22.94 | $23.68 | $22.83 | 604,809 | 03-05-2024 |
$23.3 | $23.98 | $23.3 | $23.99 | $22.63 | 1,331,736 | 03-04-2024 |
$23.71 | $23.66 | $23.71 | $24.53 | $23.585 | 1,538,751 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing ...
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia PR Newswire – Topline data expected in 4Q24 could support sNDA filing in 1H25 – – Revume...
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire – PDUFA action date set for September 26, 2024 – – NDA being reviewed under FDA's RTOR program – ...